We’re pleased to share the good news from sister charity Brain Tumour Research’s Centre of Excellence at Plymouth University about their breakthrough in meningioma.
The Brain Tumour Research Campaign holds or participates in a number of fundraising events…
Buying items from our shop helps support the Brain Tumour Research Campaign…
Find out about all upcoming and recent events supporting Brain Tumour awareness and fundraising…
The causes of brain tumours are not understood – less than 1% are preventable; for leukaemia and breast cancer 15%, and 27% cases respectively are preventable
Find out moreOur partners, supporters and researchers are frequently featured in the newspapers, on radio and television – we are always keen to promote our work and raise awareness of the desperate plight of brain tumours patients and their families and friends.
Read about some people whose lives have been touched by brain tumours – we hope you feel as inspired by them as we do!
Dan was first diagnosed with a grade 2 brain tumour after a grand mal seizure in April 2006 when he was 30. He received a variety of treatments including a craniotomy in 2009 to de-bulk the tumour. At that time he found out that the tumour had been re-classified as a grade 3 or 4 and his doctors recommended he should start to receive regular chemotherapy and radiotherapy at Charing Cross Hospital. Dan was married to Lucy and was a fundraiser for and a trustee of BTRC.
More than 12,000 people are diagnosed yearly with brain tumours. Many of these will also experience chronic pain. Fibromyalgia and arthritis are just two examples of this.
1.5 billion people around the globe are affected by chronic pain. Physical symptoms can be severe and mental health often gets pushed aside. So many people suffer from pain daily, and we must start looking at how to improve the mental impact.
Our brain tumour research programme is possibly one of the most comprehensive in the world. Its aim is to look at every possibility to improve the outlook for brain tumour patients by producing rapid “translational” research, ie research that translates into treatments as quickly as possible. We have examined every aspect of the patient pathway from diagnosis through treatment to survival and have identified areas that require improvement to achieve this.
